Company / R&D Expense
FATE THERAPEUTICS INC R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$135.0M
FY2025
5-year range
$87.8M / $320.5M
FY2021-FY2025
Trend
-21.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $320M to $135M over the past 2 years.
Based on SEC 10-K filings.
$135M in FY2025 with a 5-year CAGR of +19.2%.
Declined from $320M to $135M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +2.4%
- 5-Year CAGR
- +19.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +19.2%, indicating consistent growth.
- In FY2025, r&d expense decreased 21.8% year-over-year.
- Peak r&d expense was recorded in FY2023.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $135.0M | -21.8% |
| FY2024 | $172.6M | -46.1% |
| FY2023 | $320.5M | +155.1% |
| FY2022 | $125.6M | +43.1% |
| FY2021 | $87.8M | +56.7% |
| FY2020 | $56.0M | +63.1% |
| FY2019 | $34.4M | +29.9% |
| FY2018 | $26.5M | +33.2% |
| FY2017 | $19.9M | +20.8% |
| FY2016 | $16.4M | +36.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026